vs
Cytosorbents Corp（CTSO）与Digimarc CORP（DMRC）财务数据对比。点击上方公司名可切换其他公司
Cytosorbents Corp的季度营收约是Digimarc CORP的1.0倍（$9.2M vs $8.9M），Digimarc CORP净利率更高（-47.2% vs -59.5%，领先12.3%），Digimarc CORP同比增速更快（2.9% vs 0.9%），Digimarc CORP自由现金流更多（$895.0K vs $-4.9M），过去两年Cytosorbents Corp的营收复合增速更高（1.3% vs -5.3%）
Cytosorbents是一家公开上市企业，总部位于美国新泽西州普林斯顿，专注于血液净化领域相关医疗产品的研发与商业化，核心产品应用于重症救治场景，帮助去除患者血液中的炎性介质等有害物质。
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
CTSO vs DMRC — 直观对比
营收规模更大
CTSO
是对方的1.0倍
$8.9M
营收增速更快
DMRC
高出2.0%
0.9%
净利率更高
DMRC
高出12.3%
-59.5%
自由现金流更多
DMRC
多$5.8M
$-4.9M
两年增速更快
CTSO
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.2M | $8.9M |
| 净利润 | $-5.5M | $-4.2M |
| 毛利率 | 73.7% | 63.5% |
| 营业利润率 | -47.5% | -48.2% |
| 净利率 | -59.5% | -47.2% |
| 营收同比 | 0.9% | 2.9% |
| 净利润同比 | 27.4% | 51.4% |
| 每股收益（稀释后） | $-0.09 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTSODMRC
| Q4 25 | $9.2M | $8.9M | ||
| Q3 25 | $9.5M | $7.6M | ||
| Q2 25 | $9.6M | $8.0M | ||
| Q1 25 | $8.7M | $9.4M | ||
| Q4 24 | $9.2M | $8.7M | ||
| Q3 24 | $8.6M | $9.4M | ||
| Q2 24 | $8.8M | $10.4M | ||
| Q1 24 | $9.0M | $9.9M |
净利润CTSODMRC
| Q4 25 | $-5.5M | $-4.2M | ||
| Q3 25 | $-3.2M | $-8.2M | ||
| Q2 25 | $1.9M | $-8.2M | ||
| Q1 25 | $-1.5M | $-11.7M | ||
| Q4 24 | $-7.6M | $-8.6M | ||
| Q3 24 | $-2.8M | $-10.8M | ||
| Q2 24 | $-4.3M | $-9.3M | ||
| Q1 24 | $-6.1M | $-10.3M |
毛利率CTSODMRC
| Q4 25 | 73.7% | 63.5% | ||
| Q3 25 | 70.3% | 58.3% | ||
| Q2 25 | 70.9% | 58.8% | ||
| Q1 25 | 71.1% | 65.0% | ||
| Q4 24 | 68.4% | 60.8% | ||
| Q3 24 | 61.0% | 62.4% | ||
| Q2 24 | 73.5% | 66.1% | ||
| Q1 24 | 76.5% | 62.5% |
营业利润率CTSODMRC
| Q4 25 | -47.5% | -48.2% | ||
| Q3 25 | -30.2% | -109.7% | ||
| Q2 25 | -37.6% | -105.2% | ||
| Q1 25 | -44.5% | -128.9% | ||
| Q4 24 | -37.1% | -105.1% | ||
| Q3 24 | -56.1% | -120.4% | ||
| Q2 24 | -40.4% | -96.2% | ||
| Q1 24 | -51.8% | -109.2% |
净利率CTSODMRC
| Q4 25 | -59.5% | -47.2% | ||
| Q3 25 | -33.4% | -106.9% | ||
| Q2 25 | 20.2% | -102.6% | ||
| Q1 25 | -16.9% | -125.2% | ||
| Q4 24 | -82.7% | -99.9% | ||
| Q3 24 | -32.1% | -113.9% | ||
| Q2 24 | -48.6% | -89.3% | ||
| Q1 24 | -67.7% | -104.0% |
每股收益（稀释后）CTSODMRC
| Q4 25 | $-0.09 | $-0.18 | ||
| Q3 25 | $-0.05 | $-0.38 | ||
| Q2 25 | $0.03 | $-0.38 | ||
| Q1 25 | $-0.02 | $-0.55 | ||
| Q4 24 | $-0.14 | $-0.40 | ||
| Q3 24 | $-0.05 | $-0.50 | ||
| Q2 24 | $-0.08 | $-0.43 | ||
| Q1 24 | $-0.11 | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.2M | $12.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.9M | $40.2M |
| 总资产 | $44.2M | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTSODMRC
| Q4 25 | $6.2M | $12.9M | ||
| Q3 25 | $7.5M | $12.6M | ||
| Q2 25 | $10.2M | $16.1M | ||
| Q1 25 | $11.6M | $21.6M | ||
| Q4 24 | $3.3M | $28.7M | ||
| Q3 24 | $5.7M | $33.7M | ||
| Q2 24 | $8.5M | $41.5M | ||
| Q1 24 | $8.6M | $48.9M |
总债务CTSODMRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $13.7M | — | ||
| Q1 24 | $4.4M | — |
股东权益CTSODMRC
| Q4 25 | $5.9M | $40.2M | ||
| Q3 25 | $9.0M | $41.4M | ||
| Q2 25 | $11.6M | $46.5M | ||
| Q1 25 | $14.5M | $50.0M | ||
| Q4 24 | $11.1M | $61.4M | ||
| Q3 24 | $13.4M | $70.2M | ||
| Q2 24 | $17.4M | $77.2M | ||
| Q1 24 | $19.6M | $84.5M |
总资产CTSODMRC
| Q4 25 | $44.2M | $53.0M | ||
| Q3 25 | $45.8M | $55.4M | ||
| Q2 25 | $48.0M | $60.7M | ||
| Q1 25 | $50.8M | $66.5M | ||
| Q4 24 | $47.4M | $75.8M | ||
| Q3 24 | $47.8M | $85.0M | ||
| Q2 24 | $53.4M | $93.4M | ||
| Q1 24 | $47.1M | $99.7M |
负债/权益比CTSODMRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.23× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.8M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | $-4.9M | $895.0K |
| 自由现金流率自由现金流/营收 | -53.4% | 10.0% |
| 资本支出强度资本支出/营收 | 1.2% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.5M | $-12.3M |
8季度趋势，按日历期对齐
经营现金流CTSODMRC
| Q4 25 | $-4.8M | $991.0K | ||
| Q3 25 | $-2.6M | $-2.6M | ||
| Q2 25 | $-1.5M | $-4.7M | ||
| Q1 25 | $-3.5M | $-5.5M | ||
| Q4 24 | $-2.3M | $-4.2M | ||
| Q3 24 | $-2.5M | $-7.1M | ||
| Q2 24 | $-4.8M | $-6.8M | ||
| Q1 24 | $-4.8M | $-8.4M |
自由现金流CTSODMRC
| Q4 25 | $-4.9M | $895.0K | ||
| Q3 25 | $-2.6M | $-2.8M | ||
| Q2 25 | $-1.5M | $-4.9M | ||
| Q1 25 | $-3.5M | $-5.5M | ||
| Q4 24 | $-2.4M | $-4.2M | ||
| Q3 24 | $-2.6M | $-7.2M | ||
| Q2 24 | $-4.8M | $-6.9M | ||
| Q1 24 | $-4.9M | $-8.5M |
自由现金流率CTSODMRC
| Q4 25 | -53.4% | 10.0% | ||
| Q3 25 | -27.3% | -36.9% | ||
| Q2 25 | -16.1% | -61.0% | ||
| Q1 25 | -39.7% | -59.1% | ||
| Q4 24 | -26.3% | -49.1% | ||
| Q3 24 | -30.4% | -75.7% | ||
| Q2 24 | -54.4% | -66.1% | ||
| Q1 24 | -54.2% | -85.8% |
资本支出强度CTSODMRC
| Q4 25 | 1.2% | 1.1% | ||
| Q3 25 | 0.2% | 2.9% | ||
| Q2 25 | 0.4% | 2.5% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.8% | 0.2% | ||
| Q3 24 | 1.8% | 0.7% | ||
| Q2 24 | 0.2% | 0.3% | ||
| Q1 24 | 0.5% | 1.1% |
现金转化率CTSODMRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.78× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTSO
| Direct | $5.1M | 55% |
| Distributors And Strategic Partners | $4.2M | 45% |
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
